Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2021 06:30 ET | Source: Cancer Genetics, Inc.

Cancer Genetics and StemoniX Announce Merger Closing

Cancer Genetics, Inc. Renamed to Vyant Bio, Inc. Vyant Bio, Inc. will begin trading on Nasdaq under the symbol VYNT CHERRY HILL, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc....
March 25, 2021 09:15 ET | Source: Cancer Genetics, Inc.

Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX

Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline...
March 12, 2021 09:30 ET | Source: Cancer Genetics, Inc.

Cancer Genetics to Present at the Annual 33rd ROTH Conference

RUTHERFORD, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...
March 04, 2021 16:15 ET | Source: Cancer Genetics, Inc.

Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference

RUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...
February 16, 2021 16:45 ET | Source: Cancer Genetics, Inc.

Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules

RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
February 10, 2021 23:00 ET | Source: Cancer Genetics, Inc.

Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules

RUTHERFORD, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
February 01, 2021 17:16 ET | Source: Cancer Genetics, Inc.

Cancer Genetics Announces Closing of $10.0 Million Private Placement Priced At-the-Market

RUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
January 28, 2021 16:02 ET | Source: Cancer Genetics, Inc.

Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market

RUTHERFORD, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
January 07, 2021 16:05 ET | Source: Cancer Genetics, Inc.

Cancer Genetics to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright

RUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...
November 12, 2020 16:25 ET | Source: Cancer Genetics, Inc.

Cancer Genetics Reports Third Quarter 2020 Financial Results

RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced...

Next Page keyboard_arrow_right